2023
Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options
Tuan J, Ogbuagu O. Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options. Expert Review Of Anti-infective Therapy 2023, 21: 565-570. PMID: 37067160, DOI: 10.1080/14787210.2023.2203913.Peer-Reviewed Original ResearchConceptsTreatment optionsMultidrug-resistant HIV infectionMultidrug-resistant HIVTreatment-emergent resistanceLimited treatment optionsClinical trial dataDrug-drug interactionsBreakthrough therapy designationHIV-1 capsid inhibitorsMechanism of actionAdherence supportCompanion drugsAntiretroviral agentsHIV infectionHIV treatmentClinical trialsLenacapavirPharmacodynamic propertiesDrug AdministrationExpert opinion sectionCapsid inhibitorsTrial dataU.S. FoodClinical usesYearly treatment
2022
Dolutegravir hypersensitivity reaction: the need for strengthening pharmacovigilance systems with optimization of antiretroviral therapy in HIV programs in resource-limited settings (case report)
Adeiza M, Kekulah I, Wachekwa I, Ogbuagu O. Dolutegravir hypersensitivity reaction: the need for strengthening pharmacovigilance systems with optimization of antiretroviral therapy in HIV programs in resource-limited settings (case report). PAMJ Clinical Medicine 2022, 8 DOI: 10.11604/pamj-cm.2022.8.47.33930.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAdverse drug reactionsDrug reactionsHIV programsResource-limited settingsAntiretroviral therapyHypersensitivity reactionsAdvanced HIV diseaseLamivudine/tenofovirLamivudine/zidovudineRoutine laboratory monitoringCombination antiretroviral therapyAntiretroviral drug treatmentFirst-line cARTFeatures of anaphylaxisRelevant health educationDrug discontinuityViral suppressionHIV diseaseHIV infectionBlood workOpportunistic infectionsLaboratory monitoringNew symptomsDrug treatmentMedical treatment
2021
Gaps and Opportunities in HIV Service Delivery in High Volume HIV Care Centers in Liberia: Lessons From the Field
Adeiza MA, Wachekwa I, Nuta C, Donato S, Koomson F, Whitney J, Plyler C, Kerr L, Sackey G, Dunbar E, Talbert-Slagle K, Klar R, Marsh RH, Caldwell S, Toomey J, Ogbuagu O. Gaps and Opportunities in HIV Service Delivery in High Volume HIV Care Centers in Liberia: Lessons From the Field. Annals Of Global Health 2021, 87: 115. PMID: 34900615, PMCID: PMC8622325, DOI: 10.5334/aogh.3246.Commentaries, Editorials and LettersConceptsHIV service deliveryAntiretroviral therapyOverall health system strengtheningHuman immunodeficiency virus (HIV) infectionHealth systemNon-physician healthcare workersCascade of careCombination prevention approachesHIV care centersViral load suppressionImmunodeficiency virus infectionEbola virus disease outbreakNew HIV infectionsQuality of lifePublic health impactHealth system strengtheningVirus disease outbreakResponsive health systemART initiationHIV workforceUndiagnosed HIVViral suppressionUNAIDS targetsUniversal health coverageHIV infectionLong-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial
Ogbuagu O, Ruane PJ, Podzamczer D, Salazar LC, Henry K, Asmuth DM, Wohl D, Gilson R, Shao Y, Ebrahimi R, Cox S, Kintu A, Carter C, Das M, Baeten JM, Brainard DM, Whitlock G, Brunetta JM, Kronborg G, Spinner CD, team D, Antinori A, Apea V, Asmuth D, Avery A, Benson P, Bergin C, Berhe M, Brar I, Brinson C, Brunetta J, Burack J, Campbell T, Cespedes M, Clarke A, Coleman M, Coll J, Casal M, Creticos C, Crofoot G, Cruickshank F, Cua E, Daar E, de Wet J, DeJesus E, Del Romero Guerrero J, Dinges W, Doblecki-Lewis S, Donovan T, Dosekun O, Flamm J, Gallant J, Gerstoft J, Gilson R, Gladstein J, Grant R, Grossberg R, Haas B, Halperin J, Hardy W, Hare C, Hassler S, Hengel R, Henry W, Hodge T, Hosek S, Hurt C, Iandiorio M, Jessen H, Kegg S, Knecht G, Kronborg G, Krznaric I, LaMarca A, Larsen C, Larsen O, Lazzarin A, Leen C, Lucasti C, Mallon P, Mannheimer S, Markowitz M, Martorell C, Mayer K, Mills A, Molina J, Morris S, Mounzer K, Nwokolo N, Ogbuagu O, Osiyemi O, Petroll A, Philibert P, Phoenix J, Pialoux G, Podzamczer D, Post F, Prins M, Ramgopal M, Rashbaum B, Reeves I, Richmond G, Rieger A, Ruane P, Salazar L, Scarsella A, Schembri G, Scott M, Shalit P, Sinclair G, Sobieszczyk M, Spinner C, Stephens J, Szabo J, Taylor S, Thompson M, Tremblay C, Trottier B, Voskuhl G, Wade B, Wohl D, Workowski K, Yawetz S, Young B. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet HIV 2021, 8: e397-e407. PMID: 34197772, DOI: 10.1016/s2352-3018(21)00071-0.Peer-Reviewed Original ResearchConceptsTenofovir disoproxil fumaratePre-exposure prophylaxisTenofovir alafenamideDisoproxil fumarateBone mineral densityHIV infectionPlacebo tabletsMineral densityHIV preventionHIV-1 pre-exposure prophylaxisTransgender womenAdult cisgender menNon-inferior efficacyWeek 96 resultsPrimary efficacy outcomeCisgender menPhase 3 trialIncident HIV infectionHIV-1 infectionNon-inferiority trialLong-term safetyMore weight gainRenal safety biomarkersSelf-reported sexual behaviorStudy medication
2018
Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in Rwanda
Kambutse I, Igiraneza G, Ogbuagu O. Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in Rwanda. PLOS ONE 2018, 13: e0207650. PMID: 30475841, PMCID: PMC6261021, DOI: 10.1371/journal.pone.0207650.Peer-Reviewed Original ResearchConceptsKigali University Teaching HospitalPre-exposure prophylaxisNew HIV infectionsHealth care workersHIV infectionHIV transmissionHealth facilitiesCare workersUniversity Teaching HospitalService delivery barriersMultiple community sitesSafer sex practicesPrEP implementationHIV testingHealthcare workersSmoking cigarettesTeaching hospitalMosquito bitesPrevention servicesHIVNew infectionsHealthcare providersHealthcare professionalsPrEPSex practices
2017
Condomless sex and HIV transmission among serodifferent couples: current evidence and recommendations
Koff A, Goldberg C, Ogbuagu O. Condomless sex and HIV transmission among serodifferent couples: current evidence and recommendations. Annals Of Medicine 2017, 49: 534-544. PMID: 28409656, DOI: 10.1080/07853890.2017.1320423.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHIV transmissionSerodifferent couplesAntiretroviral therapyCondomless sexCondom useHIV-positive sexual partnerHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionPre-exposure prophylaxisHIV transmission riskUse of condomsInfected partnerHIV infectionHIV incidenceSexual transmissionHIV preventionPreventive benefitsVirus infectionCurrent evidencePrevention strategiesSexual partnersTransmission riskIndividual riskSexInfection
2015
CD8 T-Cell Lymphocytosis and Associated Clinical Syndromes in HIV-Infected Patients.
Tiberio PJ, Ogbuagu OE. CD8 T-Cell Lymphocytosis and Associated Clinical Syndromes in HIV-Infected Patients. Aids Reviews 2015, 17: 202-11. PMID: 26679852.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements